The invention relates to a vaccine comprising live attenuated recombinant alphavirus comprising mutated capsid protein. The invention also relates to a method of preventing a subject from contracting an alphaviral infection that would otherwise produce clinical signs of disease. In an embodiment the mutated capsid protein is Chikungunya virus (CHIKV) capsid protein having a mutated nucleolar localisation signal/sequence (NoLS), preferably the mutant NLS 101/95.

Disclosed herein are systems and methods for detecting and diagnosing flaviviral or alphaviral infections in subjects in need thereof. The systems and methods of the disclosure enable rapid testing of small volumes of biological sample with the ability to reliably distinguish between flavival and alphaviral infections and determine whether the viral infection is acute or chronic.

Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Chikungunya Virus (CHIKV).

The present invention relates to an immunochromatographic analysis device for detecting chikungunya virus, including a sample loading part, a labeling substance retaining part, a chromatographic medium part having a detection part, and an absorption part, wherein the labeling substance retaining part contains a first antibody against the chikungunya virus, including a specific heavy chain variable region and a specific light chain variable region or an antigen-binding fragment thereof, and the detection part contains a second antibody against the chikungunya virus, including a specific heavy chain variable region and the light chain variable region or an antigen-binding fragment thereof, and a third antibody against the chikungunya virus, including a specific heavy chain variable region and the light chain variable region or an antigen-binding fragment thereof.

The present invention provides a new antibody against ECSA type Chikungunya virus, WA type Chikungunya virus, and Asian type Chikungunya virus or an antigen-binding fragment of the antibody. The antibody against Chikungunya virus or the antigen-binding fragment of the antibody of the present invention includes a heavy chain variable region or a heavy chain (1), (2), or (3) and a light chain variable region or a light chain (4).

The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

Disclosed herein are recombinant baculoviruses suitable for detecting the presence of arthropod-borne viruses in a biological sample of a test subject. The information derived from the detection may also be used to render a diagnosis on whether the test subject is infected with the arthropod-borne viruses or not, so that proper course of treatment may be assigned to the subject.

The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

Disclosed herein are recombinant baculoviruses suitable for detecting the presence of arthropod-borne viruses in a biological sample of a test subject. The information derived from the detection may also be used to render a diagnosis on whether the test subject is infected with the arthropod-borne viruses or not, so that proper course of treatment may be assigned to the subject.

Disclosed herein are systems and methods for detecting and diagnosing flaviviral or alphaviral infections in subjects in need thereof. The systems and methods of the disclosure enable rapid testing of small volumes of biological sample with the ability to reliably distinguish between flavival and alphaviral infections and determine whether the viral infection is acute or chronic.